[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-function-aggravated\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-function-aggravated":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100546748","dapagliflozin-delays-the-loss-of-renal-function-in-peritoneal-dialysis-patients-100546748",false,"NCT06398977","Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients","Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study","Inclusion Criteria:\n\n* Patients with PD duration between 1 month and 3 months.\n* Patients aged between 18 and 75 years.\n* Voluntary signing of informed consent.\n* Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.\n* Daily urine output ≥ 400ml\u002Fday.\n* Stable PD prescription for one month.\n\nExclusion Criteria:\n\n* Pregnant and lactating women.\n* Patients with type 1 diabetes mellitus.\n* Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.\n* Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \\> 120 IU\u002FL, and other clinically confirmed severe liver diseases.\n* Patients with more than 2 episodes of urinary tract infection in the past six months.\n* Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin.\n* Patients using the following medications: rifampicin, phenytoin.\n* Patients with malignant tumors.\n* Patients who developed peritonitis within one month.\n* Patients undergoing combined hemodialysis treatment.\n* Patients with a willingness for kidney transplantation within six months.\n* Patients with a history of pancreatitis or pancreatic transplantation.\n* Patients who experienced acute coronary syndrome or cerebrovascular events within one month.\n* Hemoglobin level less than 90g\u002FL.","ALL","18 Years","75 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.",[27,28,29],"Peritoneal Dialysis Complication","Renal Function Aggravated","Sodium-glucose Co-transporter-2 Inhibitors","RECRUITING","2024-04-30",{"date":33,"type":34},"2024-05-03","ACTUAL",{"date":36,"type":34},"2024-03-11",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"Sichuan Academy of Medical Sciences","OTHER"]